ICYMI: Elotuzumab reduces progression risk in lenalidomide-refractory multiple myelomaNovember 7, 2018Lymphoma & Plasma Cell Disorders
FDA approves elotuzumab with pom/dex in refractory myelomaNovember 7, 2018Lymphoma & Plasma Cell Disorders
Sandoz halts pursuit of U.S. approval for rituximab biosimilarNovember 5, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Haploidentical transplantation holds promise in relapsed myelomaNovember 3, 2018Lymphoma & Plasma Cell Disorders
Genomic abnormalities shed light on racial disparity in myelomaNovember 1, 2018Lymphoma & Plasma Cell Disorders
Checkpoint inhibitor plus rituximab is active in non-Hodgkin lymphomaOctober 31, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Line complications plague dose-adjusted EPOCH-R in non-Hodgkin lymphomaOctober 25, 2018Lymphoma & Plasma Cell Disorders
Older age predicts mortality after alloHCT in NHL, but not relapseOctober 24, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Study challenges LVEF assessment before DLBCL treatmentOctober 19, 2018Lymphoma & Plasma Cell Disorders
Entospletinib falls short in relapsed/refractory DLBCLOctober 11, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Updated ThroLy system predicts need for thromboprophylaxisOctober 11, 2018Lymphoma & Plasma Cell Disorders
